Bimagrumab
An investigational monoclonal antibody that increases lean mass and reduces fat mass through activin type II receptor blockade. It is not a peptide.
- Human evidencen/a
- Animal evidencen/a
- Mechanisticn/a
- Safety knowledgen/a
- Editorial confidence5/5
Evidence Snapshot
- Overall
- 2/5Emerging / preliminary
- Human
- 2/5Some human clinical evidence
- Animal
- 0/5None identified
- In-vitro
- 0/5None identified
- Safety
- 2/5Partially characterised safety
Scientific identity
- Peptide family
- Activin type II receptor antibody
- Entity class
- Monoclonal antibody
- Alternative names
- BYM338
Developed as a fully human monoclonal antibody that blocks activin type II receptors, initially for muscle-wasting disorders and later obesity.
Proposed Mechanisms
- not-yet-documentedpending-editorial-review
- Activin type IIB ligand trapping →related
Reported / Studied Uses
- Body fat reductionEvidence · moderate
- Muscle massEvidence · moderate
Human Evidence
Randomized human trials show body-composition effects in obesity and type 2 diabetes, while several muscle-disease programmes failed to establish sufficient functional benefit.
Animal Evidence
Animal studies support increased muscle mass and reduced adiposity.
Safety & Unknowns
Regulatory Status
| Country | Status | Notes |
|---|
Community Observations
References
- No verified references linked yet. Editors will add primary sources.
Full Disclaimer
This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.
Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.
Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.